Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization
- 1 May 2000
- journal article
- on the-market
- Published by Springer Nature in Nature Medicine
- Vol. 6 (5) , 599-602
- https://doi.org/10.1038/75087
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vectorNature Genetics, 2000
- Full Functional Rescue of a Complete Muscle (TA) in Dystrophic Hamsters by Adeno-Associated Virus Vector-Directed Gene TherapyJournal of Virology, 2000
- Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosaNature Medicine, 1998
- In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vectorGene Therapy, 1998
- Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectorsNature Genetics, 1997
- Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABAAα1 containing receptors and increases inferior collicular seizure sensitivityBrain Research, 1997
- Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic proteinProceedings of the National Academy of Sciences, 1996
- Quantitative Analysis of the Packaging Capacity of Recombinant Adeno-Associated VirusHuman Gene Therapy, 1996
- Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brainNature Genetics, 1994
- Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector.Proceedings of the National Academy of Sciences, 1993